ArticleNeuro-oncology practice2021
Predictors of early, recurrent, and intractable seizures in low-grade glioma.
Article in Neuro-oncology practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Palliative care and end-of-life care in adults with malignant brain tumors.Neuro-oncology · 2023Pooled it
- New candidate gene mutations in astrocytoma with seizures.Scientific reports · 2025Article
- Presenting clinical and radiographic features of diffuse glioma molecular subtypes in accordance with the 2021 CNS5 WHO classification.Neuro-oncology practice · 2025Article
- Brain Tumor Related Epilepsy: Pathophysiology and Multimodal Approach to Management.Current oncology reports · 2025Review
- Seizures in brain tumors: pathogenesis, risk factors and management (Review).International journal of molecular medicine · 2025Review
- Brain tumors and fitness to drive: A review and multi-disciplinary approach.Neuro-oncology practice · 2025Review
- Epilepsy as primary tumor manifestation correlates with patient status, age, and tumor volume but not with survival in elderly glioblastoma patients: a retrospective bicentric analysis.Neurosurgical review · 2025Article
- Levetiracetam and valproic acid in glioma: antiseizure and potential antineoplastic effects.Future oncology (London, England) · 2025Review
- Candidate gene mutations of patients with astrocytoma who present with seizures: evidence from whole exome sequencing.Frontiers in oncology · 2025Article
- Elevated glioma-related cortical glutamateBrain communications · 2025Article
- Gene mutations linked to drug-resistant epilepsy in astrocytoma.Frontiers in neurology · 2025Article
- IDH mutant high-grade gliomas.Frontiers in molecular neuroscience · 2025Review
- From bench to bedside: the application of cannabidiol in glioma.Journal of translational medicine · 2024Review
- Glioma genetic profiles associated with electrophysiologic hyperexcitability.Neuro-oncology · 2024Article
- Brain tumor-related epilepsy management: A Society for Neuro-oncology (SNO) consensus review on current management.Neuro-oncology · 2024Review
- Effectiveness of Antiseizure Medication Triple Therapy in Patients With Glioma With Refractory Epilepsy: An Observational Cohort Study.Neurology · 2023Observational
- Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.Neuro-oncology · 2023Article
- DNALI1 is a prognosis-related biomarker and correlates with immune infiltrates in low grade glioma.Cancer biomarkers : section A of Disease markers · 2023Article
- Seizures in patients with IDH-mutated lower grade gliomas.Journal of neuro-oncology · 2022Article
- Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas.Neuro-oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeizures are common among patients with low-grade glioma (LGG) and can significantly affect morbidity. We sought to determine the association between the clinical and molecular factors with seizure incidence and refractoriness in LGG patients.
methodsWe conducted a retrospective review at the University of Virginia in patients with LGG (World Health Organization, WHO Grade II) evaluated between 2002 and 2015. Descriptive statistics were calculated for variables of interest, and the Kaplan-Meier method was used to estimate survival curves, which were compared with the log-rank test.
resultsA total of 291 patients were included; 254 had molecular testing performed for presence of an isocitrate dehydrogenase (
conclusionsSeizures are common among patients with LGG. Differences in preoperative or postoperative and intractable seizure rates by WHO 2016 classification were not detected. Our data showed a trend toward higher seizure incidence preoperatively in patients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.